Analyst Reco. Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
7.29 ^USD	+1.11%		+18.54%	+231.36%

04-01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
03-28	ADRs End Lower; NuCana Slides 15%	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fed Rate Outlook Weakens Exchange-Traded Funds, Equity Futures Premarket Thursday	21/09/23	MT
Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating	31/08/23	MT
Maxim Downgrades Mesoblast to Hold From Buy	07/08/23	MT
Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7	04/08/23	MT
William Blair Downgrades Mesoblast to Market Perform From Outperform	04/08/23	MT
Chardan Trims Price Target on Mesoblast to $1.50 From $2, Maintains Sell Rating	04/08/23	MT
Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating	30/05/23	MT
Cantor Fitzgerald Reiterates Mesoblast at Overweight With $23 Price Target	01/02/23	MT
Jefferies Downgrades Mesoblast to Hold From Buy	06/12/22	MT
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target	06/09/22	MT
Chardan Lowers Mesoblast's Price Target to $2.50 From $6.50, Maintains Sell Rating	03/06/22	MT
MESOBLAST : Jefferies Downgrades Mesoblast to Hold From Buy	31/08/21	MT
MESOBLAST : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating	31/08/21	MT
Mesoblast : COVID-19 Drug Remestemcel-L's ARDS Trial Enhances Survival Rate in Patients	19/07/21	MT
MESOBLAST : Maxim Group Upgrades Mesoblast to Buy From Hold, Sets $18 Price Target	07/04/21	MT
MESOBLAST : Jefferies & Co Downgrades Mesoblast to Hold From Buy	19/01/21	MT
MESOBLAST : Maxim Downgrades Mesoblast to Hold From Buy	22/12/20	MT
MESOBLAST : RBC Capital Adjusts Mesoblast's Price Target to $11 From $12, Maintains Sector Perform-Speculative Risk Rating	15/12/20	MT
MESOBLAST : Chardan Downgrades Mesoblast to Sell From Neutral, Adjusts Price Target to $7.50 From $5.50	04/12/20	MT
MESOBLAST : HC Wainwright Adjusts Mesoblast's Price Target to $20 from $19, Keeps Buy Rating	20/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Analyst Reco.

Filters